How to dose tirzepatide

The titration of tirzepatide (Tirzepatide) follows a fixed 2.5 mg ladder that goes up every 4 weeks from a starting dose of 2.5 mg, passing through 5, 7.5, 10 and 12.5 mg to reach 15 mg once a week, exactly as it was established in SURMOUNT-1 and SURMOUNT-2 [1][2]. This schedule rests on the pharmacokinetic half-life of tirzepatide (around 5 days) and leaves sufficient time, before each step up, for adaptation at receptor level to take place at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. On the 60 mg multi-dose pen from Body Pharm, every step on the ladder is dialled directly on the dial, in milligrams.

This guide covers the standard titration ladder from 2.5 to 15 mg, how each step is dialled on the pen and when a dose is raised or held, drawing on the tolerance data from the SURMOUNT studies.

Tirzepatide dosing: the essentials

• Tirzepatide is raised every 4 weeks in 2.5 mg steps from 2.5 mg up to a maximum of 15 mg a week
• The dose dial on the pen sets the dose directly in milligrams: there are no volumes to calculate
• Nausea forms a plateau across the dose range rather than rising (31–33% at therapeutic doses versus 9.5% with placebo), and that is what justifies holding each step for four weeks
• Rotating sites and a slow injection technique prevent lipohypertrophy and ensure a consistent absorption
• Store the pen between 2 and 8 °C protected from light; unopened, 24 months; 12 months from the first puncture; up to 30 days at room temperature without exceeding 30 °C

The titration ladder at a glance

The incidence of nausea in SURMOUNT-1 was 31.0% at 5 mg, 32.4% at 10 mg and 33.3% at 15 mg, versus 9.5% with placebo [1]. That plateau, rather than a progressive rise, is the pharmacological basis for holding each step for four weeks. Gastrointestinal tolerance settles before the escalation, not after it.

What tirzepatide is and how it works

Tirzepatide is a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor [1]. That dual binding to receptors is the mechanistic difference from semaglutide, which acts only as a GLP-1 agonist. The GIP arm appears to potentiate the satiety and insulinotropic effects driven by GLP-1 and, at the same time, to modulate energy expenditure, which is the working hypothesis for the stronger weight-loss signal seen in the head-to-head data [3] and in the data across studies.

In SURMOUNT-1 (Jastreboff et al., NEJM, 2022), participants without type 2 diabetes who were treated with 15 mg of tirzepatide a week achieved a mean reduction in body weight of 20.9% over 72 weeks, versus 3.1% with placebo [1]. SURMOUNT-2 (Garvey et al., Lancet, 2023) confirmed comparable, somewhat attenuated, effects in participants with type 2 diabetes using the same 2.5 mg → 15 mg ladder [2]. Those two studies are the anchor references for any titration protocol that aspires to having an evidence base.

Regulatory status as at 7 February 2026: Mounjaro (tirzepatide) holds a marketing authorisation in the EU for type 2 diabetes in adults and for weight management [4].

Scope of this protocol in research

This guide documents a titration schedule solely for the purposes of research and analysis. It is not a prescription, nor medical advice, nor a substitute for an authorised medicine that is dispensed on medical prescription. Anyone comparing GLP-1 mono-agonists with dual agonists should read, before settling on a study design, the parallel Semaglutide Dosing protocol and the mechanism breakdown in Retatrutide vs. semaglutide vs. tirzepatide.

Standard tirzepatide titration schedule (2.5 mg–15 mg)

The standard tirzepatide titration ladder is a six-step escalation from 2.5 mg to 15 mg a week, holding each dose for four weeks before moving up. That schedule was used both in SURMOUNT-1 (Jastreboff et al., NEJM, 2022) [1] and in SURMOUNT-2 (Garvey et al., Lancet, 2023) [2], and it is the reference framework with which any protocol should align itself.

Why four weeks per step

Holding for four weeks is not an arbitrary choice. It covers around five half-lives of tirzepatide (t½ ≈ 5 days) plus a margin for adaptation of the GLP-1 and GIP receptors. That rhythm explains the gastrointestinal tolerance curve observed in SURMOUNT-1: the incidence of nausea was 31.0% at 5 mg, 32.4% at 10 mg and 33.3% at 15 mg, versus 9.5% with placebo [1]. Shortening the schedule to less than four weeks per step pushes participants up the dose curve before the adaptation has been completed. The data from the studies offer no justification in terms of efficacy for doing so.

The 12.5 mg step is not optional in this protocol

Some abbreviated guides jump from 10 mg straight to 15 mg. The SURMOUNT studies did not. Both of them titrated in 2.5 mg steps every four weeks, so that 12.5 mg is a step in its own right on the authorised ladder and not an optional stopgap [1][2]. Anyone documenting fidelity to the protocol should record the 12.5 mg block expressly.

15 mg is the ceiling

15 mg a week is the highest dose studied in the SURMOUNT programme and the highest authorised maintenance dose according to the tirzepatide summary of product characteristics [1][2][4]. No published phase 3 evidence supports any escalation beyond 15 mg, and any protocol that claims otherwise is operating outside of the evidence base. For the comparison with GLP-1 mono-agonist schedules, consult the parallel Semaglutide Dosing protocol and the mechanism breakdown in Retatrutide vs. semaglutide vs. tirzepatide.

The pen: dialling each step

The Body Pharm multi-dose tirzepatide pen comes pre-filled with 60 mg and the dial sets the dose directly in milligrams. Every step on the SURMOUNT ladder, 2.5, 5, 7.5, 10, 12.5 and 15 mg, is dialled exactly as it is. There is no concentration to look up and no volume to calculate: the number on the dial is the dose.

Checking the dose before injecting

Reading the dose window at eye level before every injection is the control that is described for keeping dose fidelity throughout the whole of the titration. Noting the dialled number in the session log, alongside the date and the injection site, makes it possible to reconstruct any deviation from the protocol afterwards.

Pen temperature

Letting the pen come up to temperature for around 30 minutes before injecting reduces the viscosity of the solution and makes the injection more comfortable. Cold solution, freshly out of storage at 2–8 °C, flows more slowly through the needle. The room-temperature stability window covers that time with plenty to spare [4][5].

For the parallel protocol with a mono-agonist, consult Semaglutide Dosing.

Subcutaneous injection: step by step

The injection technique described for tirzepatide is a single weekly subcutaneous dose into the abdomen, the outer upper arm or the front of the thigh, with site rotation, a slow injection and a 5–10 second wait before withdrawing the needle [4]. The eight-step sequence below is the administration protocol described in the literature for every session, regardless of the point on the ladder you are at.

Why site rotation matters

Injecting repeatedly into the same subcutaneous site causes lipohypertrophy, palpable fibro-fatty nodules that distort the kinetics of absorption and can inadvertently attenuate the dose that is delivered. The risk is well documented across the whole GLP-1 receptor agonist class, which is why the regulatory agencies list three authorised sites rather than one [4]. In the practice described, the abdomen is divided into four zones that are worked through weekly; a quadrant that has already been used is not used again until the arm and the thigh have each received an injection.

Site selection and absorption

No pharmacokinetic study from 2024–2026 has demonstrated clinically relevant differences in tirzepatide absorption between the abdomen, the thigh and the arm, and the summary of product characteristics allows all three without any dose adjustment [4]. The abdomen remains the standard site in the majority of study protocols because it is the most convenient for self-injection at a consistent subcutaneous depth; what the protocol demands, however, is rotation, and not a preference for one site.

For the equivalent technical sequence with a mono-agonist, the Semaglutide Dosing protocol uses the same eight steps with a different titration ladder. Anyone comparing molecules before settling on a protocol should also read Retatrutide vs. semaglutide vs. tirzepatide to learn about the differences in mechanism that influence decisions on site and on scheduling.

Titration: when the dose is raised in the described protocols

The protocols that have been described only move on to the next dose after four full weeks on the current dose with tolerance established. "Tolerance established" means: no persistent nausea, no vomiting and no gastrointestinal discomfort affecting food or fluid intake in the seven days before the planned escalation. If any of these persists, the current dose is held for another four-week block and reassessed.

The SURMOUNT-1 protocol (Jastreboff et al., NEJM, 2022) expressly allowed investigators to delay escalation for tolerance reasons instead of forcing the next step according to the calendar. That is why the nausea rates described in the study form a plateau at the higher doses instead of climbing: 31.0% at 5 mg, 32.4% at 10 mg and 33.3% at 15 mg, versus 9.5% with placebo [1]. The ladder works as a ceiling, not as an obligation.

Tolerance check before moving up

Four conditions are described as prerequisites for escalation:

• Four weeks completed on the current dose
• No nausea above "mild" in the last seven days
• No vomiting episodes since the last injection
• Stable food and fluid intake

If any one of them is not met, the dose is held where it is. There is no downside in protocol terms to spending 8 or 12 weeks at 5 mg or at 7.5 mg. Several research protocols use 10 mg as the final maintenance dose and never go up to 12.5 or 15 mg, above all when the research endpoint is a metabolic one rather than maximum weight loss.

Comparison with the semaglutide rhythm

Tirzepatide escalates in 2.5 mg steps every four weeks over six steps (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg). Semaglutide uses a slower five-step ladder over a minimum of 16 weeks to reach 2.4 mg; the Semaglutide Dosing protocol walks through that schedule in full. Anyone choosing between molecules should also read Retatrutide vs. semaglutide vs. tirzepatide to understand, at receptor level, why the speeds of escalation differ.

Missed-dose protocol: what to do mid-titration

Missing a single weekly dose of tirzepatide does not reset the titration ladder. The decision rule is based on time: if fewer than 4 days have passed since the scheduled injection day, the dose is administered as soon as possible and the original day of the week is kept. If 4 days or more have passed, that dose is skipped entirely and the schedule continues on the next scheduled day at the same step. Two doses must never be administered within a 3-day period. This guidance matches the missed-dose instruction in the European SmPC for Mounjaro (EMA) [4].

Decision table

Why the ladder is not reset

The half-life of tirzepatide is around 5 days, so that at the next injection, after a week has been skipped, there is still a measurable plasma concentration. The tolerance built up over four weeks at, for example, 7.5 mg does not disappear because of a single missed injection. Restarting at 2.5 mg after a missed dose is an overcorrection with no pharmacokinetic basis [4].

Repeated absences are assessed in a different way. After two or more consecutive weeks missed, gastrointestinal tolerance at the previous step is no longer guaranteed; the prudent route is to drop down one step for four weeks before attempting the escalation again. The same logic applies to semaglutide protocols, as described in Semaglutide Dosing.

Storage and handling of tirzepatide pens

Store the pen between 2 and 8 °C, protected from light, and never freeze it. Unopened, the shelf life is 24 months. Once the cartridge has been punctured for the first time, the pen is used within 12 months. If you do not have a fridge available, it remains stable at room temperature for a maximum of 30 days, without exceeding 30 °C. Bring the pen up to temperature before injecting [4][5].

The date of the first puncture should be written on the pen with a permanent marker, so that the 12-month window and the cumulative time out of the fridge can be counted from there.

The pen must not be shaken at any point. Tirzepatide is a peptide; mechanical agitation can denature the active molecule or generate micro-bubbles that interfere with the delivery. The cartridge should be inspected before every injection: the solution must be clear and colourless and must be discarded immediately if it looks cloudy or discoloured or if it contains visible particles.

Storage in brief

The same storage rules apply to the other pre-filled pens in the range; the broader comparison of peptide stability is in Retatrutide vs. semaglutide vs. tirzepatide.

Tirzepatide vs. semaglutide: key protocol differences

Tirzepatide and semaglutide share the same 4-week escalation rhythm and the weekly injection schedule, but they differ in receptor target and in the absolute mg range. The table shows the operational differences that are worth knowing before switching from one protocol to the other.

The 6-fold difference between the maximum doses (15 mg versus 2.4 mg) does not amount to a 6-fold difference in potency. The dual GIP/GLP-1 binding profile of tirzepatide means that the absolute mg values are not interchangeable milligram for milligram with semaglutide. The data from the studies do not support a conversion by means of a simple ratio.

Reference values from the studies

SURMOUNT-1 (Jastreboff et al., NEJM 2022) used the tirzepatide ladder of 2.5 mg–15 mg in 4-week steps and described nausea in 31.0% (5 mg), 32.4% (10 mg) and 33.3% (15 mg), versus 9.5% with placebo [1]. SURMOUNT-2 applied the same ladder in participants with type 2 diabetes [2]. STEP-1 (Wilding et al., NEJM, 2021) is the equivalent semaglutide reference for the 2.4 mg endpoint [6].

For the parallel protocol with semaglutide, consult Semaglutide Dosing. For the receptor-level comparison of the three peptides, including the triple agonism of retatrutide, consult Retatrutide vs. semaglutide vs. tirzepatide.

Common adverse effects in research

Gastrointestinal events dominate the tirzepatide safety profile in the study literature; nausea is described in around a third of participants at therapeutic doses. In SURMOUNT-1, the incidence of nausea was 31.0% at 5 mg, 32.4% at 10 mg and 33.3% at 15 mg, versus 9.5% with placebo [1]. The pattern is dose-dependent, but it forms a plateau rather than a steep climb, and the same ladder produced a comparable adverse-effect profile in SURMOUNT-2 [2].

Gastrointestinal effects cluster in the first one or two weeks after each step up the ladder and usually subside before the next escalation window. The solution documented in the SURMOUNT programme is mechanical, not pharmacological: hold the current dose for a further four weeks rather than reducing the target dose that had been planned [2]. The same logic applies in Semaglutide Dosing and should be borne in mind when comparing tolerance with other incretin analogues in Retatrutide vs. semaglutide vs. tirzepatide.

Frequency of adverse events in SURMOUNT-1 (Jastreboff et al., NEJM 2022)

The majority of the gastrointestinal events in SURMOUNT-1 were classified as mild or moderate and appeared mainly during dose escalation, not during maintenance [1]. Discontinuations due to adverse events remained in the minority in the 5 to 15 mg arms [1].

Notice: the figures above are data from the research literature of clinical trials in defined patient populations. They are not medical advice, they do not replace an individual clinical assessment and they do not constitute a recommendation to self-administer tirzepatide outside a regulated prescription pathway.

Frequently Asked Questions

Can tirzepatide be injected into the arm?

Yes. The outer upper arm is a validated subcutaneous site, alongside the abdomen and the thigh, and the regulatory agencies do not require any dose adjustment between sites [4]. No pharmacokinetic study from 2024–2026 has demonstrated clinically relevant differences in absorption between the abdomen, the thigh and the arm [4]. Even so, standard site rotation is recommended in order to limit local irritation and to avoid lipohypertrophy [4].

What is the maximum dose of tirzepatide?

The highest maintenance dose studied and authorised is 15 mg once a week, as used in the highest-dose arm of SURMOUNT-1 (Jastreboff et al., NEJM 2022) [1]. SURMOUNT-2 (Garvey et al., Lancet 2023) used the same 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg ladder in 4-week steps [2].

How many doses does a pen contain at each step?

Approximate number of doses per 60 mg pen, assuming complete delivery of the entire peptide content:

The number on the dial is the dose that is delivered, so that the count is obtained by dividing the total content by the step dialled.

Does tirzepatide need to be refrigerated after first use?

Yes. The pen goes back into the fridge (2–8 °C) between injections and is used within the 12 months following the first puncture. If no fridge is available, it tolerates up to 30 days at room temperature without exceeding 30 °C [4][5].

How does tirzepatide differ from retatrutide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist; retatrutide is a triple agonist that additionally activates the glucagon receptor. The mechanism, the titration intervals and the tolerance profiles differ to such an extent that the protocols are not interchangeable. Consult Retatrutide vs. semaglutide vs. tirzepatide for the direct comparison and Semaglutide Dosing for the mono-agonist titration schedule.

Tirzepatide pens for research in Spain

Body Pharm supplies tirzepatide in a 60 mg multi-dose pen for the purposes of research and analysis; shipping is to Spain. A full 2.5 → 15 mg titration ladder consumes 120 mg or more of peptide over the course of a 20-week protocol, so that a long protocol needs more than one pen.

All pens are sold solely for research and laboratory purposes and are not intended for administration to people or to animals. Consult the weight-loss peptides category to see current stock, or compare the titration mechanics with the Semaglutide Dosing protocol and with the Retatrutide vs. semaglutide vs. tirzepatide breakdown before settling on a peptide for a specific study design.

Next steps

The starting step is dialled on the pen and noted in the session log together with the date and the injection site. From there on, every step up waits for four full weeks and a tolerance check. Anyone comparing tirzepatide with semaglutide or retatrutide should read the parallel protocols and the mechanism breakdown, so that the study design takes into account the receptor-level differences between the molecules.

Sources

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov/35658024
2. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. pubmed.ncbi.nlm.nih.gov/37385275
3. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov/34170647
4. EMA, EPAR and summary of product characteristics (SmPC) for Mounjaro (tirzepatide): escalation in 2.5 mg steps at intervals of at least 4 weeks, injection sites and storage. ema.europa.eu
5. Body Pharm product specification: pre-filled multi-dose tirzepatide 60 mg pen, 3 ml cartridge, dial in milligrams, storage at 2–8 °C, 24 months unopened and 12 months from the first puncture, up to 30 days below 30 °C without a fridge. Supplier specification, not a study.
6. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov/33567185